• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.阿仑单抗联合氟达拉滨治疗复发或难治性B细胞慢性淋巴细胞白血病患者的药代动力学
Haematologica. 2009 Jan;94(1):150-2. doi: 10.3324/haematol.13379. Epub 2008 Nov 10.
2
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.在晚期慢性淋巴细胞白血病中，氟达拉滨诱导序贯阿仑单抗巩固治疗后骨髓血管生成的强烈逆转。
Haematologica. 2007 Oct;92(10):1367-74.
3
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.氟达拉滨难治性慢性淋巴细胞白血病患者连续输注阿仑单抗的初步经验。
Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21.
4
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.奥法妥木单抗治疗新诊断和复发/难治性慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
5
Treatment of fludarabine-refractory chronic lymphocytic leukemia.氟达拉滨难治性慢性淋巴细胞白血病的治疗。
Cancer. 2009 Jul 1;115(13):2824-36. doi: 10.1002/cncr.24329.
6
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.阿仑单抗（Campath-1H）治疗慢性淋巴细胞白血病
Oncogene. 2007 May 28;26(25):3644-53. doi: 10.1038/sj.onc.1210380.
7
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.氟达拉滨联合疗法治疗慢性淋巴细胞白血病
Clin Lymphoma. 2002 Jun;3(1):26-35. doi: 10.3816/clm.2002.n.008.
8
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.在对氟达拉滨产生反应后使用阿仑单抗进行巩固治疗，对清除慢性淋巴细胞白血病患者的残留疾病有效。
J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17.
9
Alemtuzumab in chronic lymphocytic leukemia.阿仑单抗治疗慢性淋巴细胞白血病
Future Oncol. 2007 Feb;3(1):29-42. doi: 10.2217/14796694.3.1.29.
10
Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.探寻慢性淋巴细胞白血病的治愈之路：巩固策略引领前行。
Leuk Lymphoma. 2009 Oct;50(10):1557-8. doi: 10.1080/10428190903161083.

引用本文的文献

1
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.一项评估 PRO131921（一种新型抗 CD20 单克隆抗体）在复发/难治性 CD20+惰性 NHL 患者中的安全性和药代动力学的 I 期临床研究：临床应答与 AUC 药代动力学的相关性。
Clin Immunol. 2014 Sep;154(1):37-46. doi: 10.1016/j.clim.2014.06.005. Epub 2014 Jun 11.
2
Alemtuzumab for patients with chronic lymphocytic leukaemia.阿仑单抗用于慢性淋巴细胞白血病患者。
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD008078. doi: 10.1002/14651858.CD008078.pub2.
3
Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.皮下注射阿仑单抗的药代动力学特征与慢性淋巴细胞白血病患者临床反应的关系。
Haematologica. 2011 Jun;96(6):932-6. doi: 10.3324/haematol.2010.033159. Epub 2011 Feb 17.
4
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.阿仑单抗治疗中危-1 骨髓增生异常综合征患者可使血细胞计数和细胞遗传学缓解持续改善。
J Clin Oncol. 2010 Dec 10;28(35):5166-73. doi: 10.1200/JCO.2010.29.7010. Epub 2010 Nov 1.

本文引用的文献

1
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.阿仑单抗与苯丁酸氮芥作为慢性淋巴细胞白血病一线治疗的比较。
J Clin Oncol. 2007 Dec 10;25(35):5616-23. doi: 10.1200/JCO.2007.12.9098. Epub 2007 Nov 5.
2
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.阿仑单抗（Campath）在慢性淋巴细胞白血病患者中的群体药代动力学-药效学及其与治疗反应的关联。
Br J Clin Pharmacol. 2007 Sep;64(3):278-91. doi: 10.1111/j.1365-2125.2007.02914.x. Epub 2007 May 16.
3
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.在对氟达拉滨产生反应后使用阿仑单抗进行巩固治疗，对清除慢性淋巴细胞白血病患者的残留疾病有效。
J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17.
4
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.氟达拉滨联合阿仑单抗治疗复发或难治性B细胞慢性淋巴细胞白血病患者有效且可行：一项II期试验结果
J Clin Oncol. 2005 Oct 1;23(28):7024-31. doi: 10.1200/JCO.2005.01.9950. Epub 2005 Sep 6.
5
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗化疗免疫疗法作为慢性淋巴细胞白血病初始治疗的早期结果。
J Clin Oncol. 2005 Jun 20;23(18):4079-88. doi: 10.1200/JCO.2005.12.051. Epub 2005 Mar 14.
6
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗联合化疗免疫疗法治疗复发难治性慢性淋巴细胞白血病。
J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14.
7
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.慢性淋巴细胞白血病患者经静脉或皮下给药途径后阿仑单抗的血药浓度及抗球蛋白反应
Blood. 2004 Aug 15;104(4):948-55. doi: 10.1182/blood-2004-02-0593. Epub 2004 Apr 15.
8
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.阿仑单抗用于既往接受过治疗且已接受氟达拉滨治疗的慢性淋巴细胞白血病患者。
J Clin Oncol. 2002 Sep 15;20(18):3891-7. doi: 10.1200/JCO.2002.06.119.
9
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).皮下注射抗CD52单克隆抗体阿仑单抗（Campath-1H）作为B细胞慢性淋巴细胞白血病（B-CLL）患者一线治疗的II期试验。
Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159.
10
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.阿仑单抗（Campath-1H）在氟达拉滨治疗失败患者中的治疗作用：一项大型国际研究的结果
Blood. 2002 May 15;99(10):3554-61. doi: 10.1182/blood.v99.10.3554.

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

作者信息

Elter Thomas, Kilp Julia, Borchmann Peter, Schulz Holger, Hallek Michael, Engert Andreas

出版信息

Haematologica. 2009 Jan;94(1):150-2. doi: 10.3324/haematol.13379. Epub 2008 Nov 10.

DOI:10.3324/haematol.13379
PMID:19001286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2625426/
Abstract
摘要